4.7 Article

Synthesis and approbation of new neuroprotective chemicals of pyrrolyl- and indolylazine classes in a cell model of Alzheimer's disease

Journal

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 222, Issue -, Pages -

Publisher

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.113577

Keywords

Alzheimer's disease; Amyloid-beta; Chaperones; Neuroprotectors; Pyrrolylazines; Viability

Funding

  1. Russian Foundation for Basic Research [19-34-80051, 20-33-70102]
  2. Russian Science Foundation [18-74-10087]
  3. Ministry of Science and Higher Education of Russia [075-15-2020-795, 13.1902.21.0027]
  4. Russian Science Foundation [18-74-10087] Funding Source: Russian Science Foundation

Ask authors/readers for more resources

Chemicals that induce the synthesis of heat shock proteins have been shown to improve neuronal survival and provide neuroprotective effects in the pathogenesis of Alzheimer's disease.
One of the major causes of neurodegeneration in the pathogenesis of Alzheimer's disease is the accumulation of cytotoxic amyloid species within the intercellular compartments of the brain. The efficacy of the anti-proteotoxic mechanism based on the molecular chaperones Hsp70 and Hsp90 in numerous types of neurons is often low, while its pharmacological enhancement has been shown to ameliorate the physiological and cognitive functions of the brain. Suggesting that the chemicals able to induce heat shock protein synthesis and therefore rescue neural cells from cytotoxicity associated with amyloid, we have synthesized a group of pyrrolyl- and indolylazines that cause the accumulation of heat shock proteins, using a novel method of photocatalysis that is employed in green chemistry. The selected compounds were tested in a cell model of Alzheimer's disease and demonstrated a pronounced neuroprotective effect. These substances increased the survival of neurons, blocked the activation of beta-galactosidase, and prevented apoptosis in neurons cultured in the presence of beta-amyloid. (C) 2021 Elsevier Masson SAS. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available